Laura Walsh

Company Overview, AstraZeneca acquired Alexion

• Returned to the field 7/22, upon request, covering Tampa, St Petersburg, Clearwater, representing the Andexxa brand since launch in 2018
• Member of the 200 Club, 219.5% to plan, Oct 30, 2024
• Executed Sales Activities and leveraged relationships to promote Andexxa in Hospitals and physician offices
• Contributed as a mentor to new hires, participated in the interview process
• Collaborated with One KAM team; MSL, National Accounts, CEL-Customer Engagement
• Leader, to ensure standardization of clinical message, call points and timing of activities
• Aligned with Speakers and coordinated education for speaker programs, office in-services and virtual webinars
• Identified and aligned with advocates to submit a formal request for BayCare-review, P&T added Andexxa back to formulary August 22, 2024
• MVP, Southeast Region, voted by peers, 2022
• (Astra Zeneca acquired Alexion)

• Company Overview, Alexion acquired Portola.
• Responsibilities included gathering insights from Key Opinion Leaders in South Florida, through Congress meetings and live and virtual interactions.
• Developed insight questions for the TLL national team, member of the Insight Sub Committee
• Managed the speakers bureau for the SE, clinical training
• Collaborated with cross functional matrix partners in sales, market access and medical

• Responsibilities included sales and marketing of Andexxa
• Call points included Neurologists, Neurosurgeons, Critical Care, Emergency, GI, Trauma Surgeons and Pharmacy
• Territory: St Petersburg, Clearwater, New Port Richey
• 2019 Culture Award Winner, Florida Region (voted by peers)
• 2019, May BayCare Formulary win
• Developed strong relationships with clients, leading to increased customer satisfaction and repeat business.
• Assessed reports to evaluate performance, develop targeted improvements, and implement changes.
• Developed and implemented strategies to improve customer service and increase sales.

• Responsibilities included sales and marketing of IL-23 biologic for Psoriasis and profiling Dermatologists, while pending approval of medication
• Territory: Tampa, Clearwater, Gainesville
• Developed strong relationships with key decision-makers, fostering trust and loyalty in the assigned territory.
• Demonstrated exceptional presentation skills during client meetings, showcasing product benefits and value propositions effectively.

• Responsibilities included sales and marketing of Auryxia for hyperphosphatemia, call points included Nephrologists and Dialysis Centers
• Territory: Tampa, Lakeland and Port Charlotte
• Q1 2017 195% to plan
• April 2016: 30% to plan, Q2 :60% to plan, July 80% to plan
• Drug on hold from Aug 1, 2016 to Nov 15, 2016
• 2016 - Increased sales two-fold upon re-entry, Nov 14- Dec 31st
• Educated customers about product features and benefits to aid in selecting best options for each individuals' needs.
• Built strong client relationships through consistent communication and effective problem solving.
• Followed up with customers after completed sales to assess satisfaction and resolve technical or service concerns.
• Provided ongoing support to existing clients, maintaining a high level of satisfaction and encouraging repeat business.

• Company Overview: (2015 Cubist acquired by Merck ~ January 20, 2016)
• Responsibilities included sales and marketing of Cubicin, Dificid, Entereg, Sivextro, Zerbaxa
• Call points included, Infectious Disease, Internal Medicine/Hospitalists, Surgeons, Emergency, Pharmacy
• Territory: Palm Harbor, New Port Richey, Brooksville, Crystal River
• 2015 Top 10 for Cubicin and Sivextro sales
• 2015 Zerbaxa and Sivextro formulary win, Florida Hospital
• 2014 COE, Circle of Excellence, Italy
• MVP, SE Region
• Appointed Marketing Advisory Member H1
• Aug 14 -Dificid Formulary win, Florida Hospital North Pinellas
• #4 in Central Area for Sivextro Sales (4th product in portfolio)
• #11 in Nation for Sivextro Sales, $90,000
• 2013 COE, Circle of Excellence, Spain
• Consistency Award, The only CBM in the Central Region to be above the company national average, for all 3 agents
• 107% to plan for Cubicin, 139 % to plan for Entereg , 100% to plan Dificid
• CBM with highest growth for HCA in region, 43% growth
• Appointed Entereg Marketing Advisory Member
• Appointed Dificid Marketing Advisory Member
• MVP, SE Region
• 107 % to plan
• May YTD, 100% to plan, 45% growth from Q1 to Q2
• Dificid Formulary Win, Community New Port Richey
• Opened Dr
• Laartz, ID and Dr
• Sastry, ID MD, Infusion Centers
• Ranked #1 in Skin Infection Contest, Q2 growth from previous quarter 2011 109% to plan
• Promoted to Senior CBM
• MVP, SE Region; 2006, 2010
• Signed Gulfcoast Oncology, for Regional Direct Account
• Conducted a Regional Workshop, “Stop Telling & Start Selling”
• Received Rolex watch, $4 million dollar club
• Received Golden Cube Award/Mentor for new hires, regionally and nationally 2007
• Attended specialized sales training, Dr Cialdini Seminar
• (2015 Cubist acquired by Merck ~ January 20, 2016)